Day One welcomes the Pediatric Neuro-Oncology community to ISPNO! Connect with peers at our reception and hear from Day One leaders on the collaboration between academia and industry in advancing pediatric drug development. Learn more and register here: https://bit.ly/3xxJ6CC
Day One Biopharmaceuticals
Biotechnology Research
Brisbane, California 14,612 followers
Cancer drug development comes of age.
About us
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
- Website
-
http://www.dayonebio.com
External link for Day One Biopharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, California
- Type
- Public Company
- Founded
- 2018
- Specialties
- Oncology, Cancer, Drug Development, Biotechnology, Pediatric Oncology, Targeted Therapies, MAPK, Neuro-Oncology, Glioma, Childhood Cancer, Translational Medicine, Hematology, and Glioma
Locations
-
Primary
Get directions
2000 Sierra Point Pkwy
Brisbane, California 94005, US
Employees at Day One Biopharmaceuticals
Updates
-
Today, we announced the expansion of our pipeline with a clinical-stage antibody drug conjugate (ADC) targeting PTK7 in solid tumors for adult and pediatric cancers. DAY301 is an important continuation of our mission to transform outcomes for patients of all ages living with cancers. Learn more: https://lnkd.in/gg_jwggu
-
-
We recently published a framework for multistakeholder collaboration in pediatric cancer research and drug development based upon a case study of the tovorafenib journey. Co-authored by colleagues and collaborators, the framework specifies roles and responsibilities for effective collaboration between industry, academia, and non-profit organizations to bring new hope to children with cancer and their families. See the highlights below and access the full white paper here: https://bit.ly/4bYoLF7
-
It's great to be back at ASCO! Visit Day One at booth 34143 to say hello and learn more about how we are addressing the critical unmet need for children with brain tumors. #ASCO24
-
-
As #BrainTumorAwarenessMonth comes to an end, we are reminded of the urgent needs of those impacted by brain tumors. We are passionately #CommittedFromDayOne to increasing awareness for this community. Learn more: https://bit.ly/3wX29WU #BTAM #GoGrayinMay
-
-
We're gearing up for this year's American Society of Clinical Oncology (ASCO) Annual Meeting and we're excited to see everyone in Chicago! If you're attending #ASCO24, stop by booth 34143 to meet the Day One team and learn more about how we're bringing novel targeted therapies to children with brain tumors.
-
-
#ICYMI catch part two of this webinar with personal advice on how to best advocate for children with pediatric low-grade glioma (#pLGG). Watch here: https://bit.ly/4bnInCT
-
This past weekend, some of our Denver-based Day One team members came together to participate in the local 2nd Annual Tumor Trot. Supporting the fight against childhood brain tumors is a cause we deeply believe in. #BrainTumorAwareness #BTAM #GoGrayinMay
-